[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pelvic-organ-prolapse-pop\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pelvic-organ-prolapse-pop":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,74,104,138,170,194,223,251,287,315,342,369,400,424,450],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100634821","poly-l-lactic-acid-for-vulvovaginal-tissue-regeneration-100634821",false,"NCT07544667","Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration","Intravaginal Injection of Poly-L-Lactic Acid for Treatment of Cystocele: A Randomized Trial","Inclusion Criteria:\n\n* Age \\> 21\n* Stage II POP of anterior vaginal wall (Ba ≥ -1)\n* Symptomatic bulge symptoms\n\n  * Positive response to PFDI-20 question 3: Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?\n  * AND any degree of bother. Providing any answer other than \"not at all\" to \"how much does this bother you\"\n* Abstinent, on contraception, or postmenopausal at time of injection\n* Must read or understand English\n\nExclusion Criteria:\n\n* Concurrent apical or posterior prolapse \\> stage 1\n* Prior pelvic radiation\n* Previous vaginal reconstructive surgery (Except total vaginal hysterectomy or sling)\n* History of chronic vaginal infections (ex. Sexually transmitted infection or bacterial vaginosis)\n* Prior vaginal laser treatment \\\u003C 6 months\n* Planned vaginal laser\u002Ftopical treatment\n* History of hypertrophic reaction to vicryl (polyglactin-910)\n* Allergy to Sculptra aesthetic or any components of Sculptra (PLLA, carboxymethylcellulose, non-pyrogenic mannitol)\n* Allergy to silicone\n* Premenopausal without contraception or abstinence during treatment phase\n* Currently breastfeeding\n* Connective tissue disorder\n* Uncontrolled diabetes (defined as HbA1c \\> 8)\n* Does not read or understand English\n* Inability to provide informed consent\n* Physical limitations that would prevent subjects from performing the required pelvic wand massage sessions after each injection, such as significant arthritis or other mobility limitations.\n* Prescription anticoagulation therapy that cannot be safely discontinued (Aspirin and anti-platelet therapies would be considered acceptable)\n* Current use of other treatments for prolapse, such as pessary, in subjects who are unwilling to discontinue these treatments during the study period.\n* Planning to start pelvic floor physical therapy during the study\n* Undergoing physical therapy and not willing to stop internal therapy for 2 weeks after an injection or biopsy","FEMALE","21 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure. Millions of women in the United States are affected, and the number is expected to rise significantly in the coming decades. Current treatments either involve conservative measures or surgery. Surgery may lead to changes in vaginal topography and scar tissue, both of which impact sexual function. There are no treatment options that restore vaginal tissue strength and preserve, even optimize, sensation and blood flow to the vagina. This project will evaluate the use of poly-L-lactic acid (PLLA), an FDA-approved biostimulant for dermatologic use with an expansive safety profile over the past decade, in the treatment of anterior wall POP and its impact on sexual function. Our study will compare intravaginal injection of PLLA vs. placebo in women with stage 2 cystocele and investigate safety and preliminary efficacy of PLLA. Prior study of regenerative biologics for the vulva and vagina have shown great promise, but use of these has not been explored for POP. This randomized controlled trial has the potential to shift the paradigm of prolapse management from surgical reconstruction to regeneration. This shift will prevent the risks of surgery and has the potential to improve sexual function and quality of life by resolving POP.",[26,27,28],"Pelvic Organ Prolapse (POP)","Cystocele","Pelvic Floor Disorder",[30,31,32,33,34,35],"regenerative medicine","biostimulant","tissue regeneration","pelvic floor disorder","pelvic organ prolapse","cystocele","NOT_YET_RECRUITING","2026-06-02",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":20},"2026-07",{"date":44,"type":20},"2028-06",{"name":46,"class":47},"Cassandra Kisby","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100589460","evaluation-of-a-personalizable-pessary-for-pelvic-organ-prolapse-100589460","NCT06954701","Evaluation of a Personalizable Pessary for Pelvic Organ Prolapse","Evaluation of a Novel Personalizable Pessary for the Treatment of Pelvic Organ Prolapse","NPP-POP","Inclusion Criteria:\n\n* Patients assigned female at birth\n* At least 18 years old at time of screening\n* Patients with symptomatic POP using a pessary for ≥ 3 months\n* Capable of giving informed consent\n* Fluency in English\n\nExclusion Criteria:\n\n* Pregnancy\n* Short vaginal length (total vaginal length \\\u003C5 cm) or subjective vaginal narrowing\n* Vaginal erosion due to current pessary\n* Presence of vesicovaginal fistula\n* Presence of rectovaginal fistula\n* Current treatment for vaginal, rectal, or bladder tumor\n* Presence of open wound or tear near vagina or anus by exam prior to removal of current pessary\n* Presence of pelvic, vaginal, or urinary infection requiring treatment\n* Ongoing treatment of recurrent urinary tract or vaginal infections\n* Inflammatory bowel disease\n* Chronic pain syndromes of pelvic or anorectal origin\n* Previous pelvic floor surgery in last 12 months\n* Congenital malformation of bladder, rectum, or vagina\n* Significant medical condition interfering with study participation (psychologic, neurologic, active drug\u002Falcohol abuse, ambulatory restrictions, etc.)\n* Planning pregnancy in next 6 months","18 Years",{"count":59,"type":20},43,[23],"Pelvic organ prolapse (POP) is a common health issue. It will impact about half of Canadian women over their lifetime. With POP, organs like the bladder, uterus, and bowel may push into the vagina. Women may experience urine leakage, physical discomfort, and embarrassment. Aside from surgery, a common treatment for POP is the use of pessaries. Pessaries are removable devices placed inside the vagina that can relieve POP symptoms. Unfortunately, pessaries have fixed sizes and three in ten patients cannot find the right fit. Pessaries can cause bleeding and discomfort if they do not fit well or are not removed and cleaned regularly. Almost half of patients who wear pessaries stop using them because of these issues. There is a need for a better pessary treatment for patients.\n\nThe investigators have developed a new pessary that has the natural shape of the vagina. This pessary is easier to remove and re-insert. The pessary is also custom fit for each patient. In this study, the investigators will compare our new pessary to traditional pessaries. Study participants who have been fit with a traditional pessary will be asked to use our new pessary design for 3 months. Study participants will fill out questionnaires about their POP symptoms. The investigators will also ask patients to provide their feedback on comfort and how easy it is to use the new pessary. This study could open up new possibilities for treating POP across Canada and around the world.",[26],[64,65],"Pelvic Organ Prolapse","Pessary","RECRUITING",{"date":39,"type":40},{"date":69,"type":40},"2026-04-30",{"date":71,"type":20},"2026-10",{"name":73,"class":47},"University of Alberta",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100638472","urinary-continence-after-vaginal-surgery-for-genital-prolapse-in-the-spanish-population-100638472","NCT07628036","Urinary Continence After Vaginal Surgery for Genital Prolapse in the Spanish Population.","Inclusion Criteria:\n\n* Women who will undergo vaginal surgery for pelvic organ prolapse\n\nExclusion Criteria:\n\n* inhability to give consent to the study","99 Years",{"count":82,"type":20},1042,"1 Year","OBSERVATIONAL","Surgical correction of pelvic organ prolapse (POP) may be associated with the development of postoperative stress urinary incontinence (SUI). This clearly affects women's satisfaction and their quality of life, and may require subsequent medical and\u002For surgical treatments.\n\nOn the other hand, pre-existing SUI could resolve after corrective prolapse surgery. Similarly, urge urinary incontinence (UUI) could appear or improve after vaginal POP surgery. Therefore, it is of paramount importance to know the prevalence of urinary incontinence after POP vaginal surgery and incontinence resolution in our population. Identifying the risk factors for the development of urinary incontinence may allow to provide individualized treatment.",[26,87,88],"Pelvic Organ Prolapse Vaginal Surgery","Urinary Incontinence (UI)",[90,91,92,93,94],"Pelvic organ prolapse","Vaginal surgery","Urinary incontinence","Stress urinary incontinence","Urge-urinary incontinence","2026-06-01",{"date":39,"type":40},{"date":98,"type":20},"2026-08-01",{"date":100,"type":20},"2028-05-30",{"name":102,"class":47},"Hospital Universitari Vall d'Hebron Research Institute",4,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":48},"100641229","phase-4-suzetrigine-for-opioid-sparing-postoperative-analgesia-following-transvaginal-pelvic-reconstructive-surgery-100641229","NCT07600697","Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Undergoing elective transvaginal pelvic reconstructive surgery at UCLA with planned same-day discharge or 23-hour observation.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Chronic opioid use.\n* Liver failure.\n* End-stage renal disease (ESRD).\n* Chronic pain syndromes, including:\n\nFibromyalgia Interstitial cystitis Chronic pelvic pain\n\n* Contraindication to acetaminophen or ibuprofen.\n* Use of strong CYP3A4 inhibitors within 7 days prior to surgery or anticipated need during the treatment period.",{"count":111,"type":20},120,[113],"PHASE4","Suzetrigine is a selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. This single-center stepped-wedge randomized clinical trial evaluates whether a suzetrigine-based postoperative analgesic regimen provides non-inferior pain control compared with standard opioid-inclusive care following transvaginal pelvic reconstructive surgery. The study will enroll 120 participants and assess pain, opioid consumption, adverse events, and functional recovery.",[26,116,117],"Stress Urinary Incontinence (SUI)","Postoperative Pain",[119,120,121,122,123,124,125,126,34,127,128,129],"Suzetrigine","NaV1.8 Inhibitor","Non-opioid analgesic","pelvic reconstructive surgery","transvaginal surgery","postoperative pain","opioid-sparing analgesia","multimodal pain management","randomized clinical trial","stepped-wedge design","phase 4 trial","2026-05-29",{"date":37,"type":40},{"date":133,"type":20},"2026-07-01",{"date":135,"type":20},"2028-07-01",{"name":137,"class":47},"University of California, Los Angeles",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":169},"100626071","the-recover-study---postpartum-recovery-of-pelvic-floor-structures-and-the-impact-of-early-rehabilitation-100626071","NCT07430865","The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation","The RECOVER Study - Recovery of Pelvic Floor Structure and Function After Vaginal Childbirth- a Longitudinal Cohort Study With an Embedded Pilot Trial","RECOVER","Inclusion Criteria:\n\n* Individuals (over 18 years) who delivered a single child vaginally between 37 and 41 weeks of gestation, with a birthweight of at least 2500 grams.\n\nExclusion Criteria:\n\n* Delivered via c-section\n* Multiparous with previous third- or fourth-degree tears\n* History of major urogynecological surgery\n* Known neurological disorder (e.g., stroke, multiple sclerosis) that could affect the assessment outcomes\n* Severe connective tissue disorders that could affect the assessment outcomes\n* New pregnancy of more than 6 weeks during the study period\n* Pain with vaginal penetration, tampon use, or gynecological examinations that would prevent participation in assessments\n* Visible signs for wound complications assessed via REEDA tool (redness, oedema, ecchymosis, discharge, approximation) will exclude the participants from the first ultrasound assessment and vaginal palpation.",true,{"count":148,"type":20},380,[23],"The goal of this observational study with an embedded pilot clinical trial is to learn how the pelvic floor recovers after vaginal childbirth and whether early individualized pelvic floor muscle training can improve recovery in people who experience pelvic floor symptoms after vaginal delivery. The main questions it aims to answer are:\n\n* How do pelvic floor muscles and surrounding tissues change and recover during the first year after vaginal childbirth?\n* How are these structural changes and their recovery related to urinary, bowel, and vaginal symptoms?\n* In participants with pelvic floor symptoms after vaginal childbirth, does early individualized pelvic floor muscle training improve symptoms and support structural recovery compared with usual care?\n\nResearchers will compare participants who receive the early pelvic floor muscle training to those receiving standard postpartum care to see if the training helps improve pelvic floor function and reduce symptoms.\n\nParticipants will:\n\nAttend clinic visits at six weeks, and six months after childbirth\n\nComplete questionnaires about urinary, bowel, and vaginal symptoms, as well as physical activity and quality of life at six weeks, and four, six months, and twelve months after childbirth\n\nUndergo clinical pelvic floor assessments, including vaginal palpation of muscle strength, tone, and perineal body stability\n\nHave ultrasound examinations of the pelvic floor to assess muscle structure, tissue integrity, and perineal body morphology\n\nFor those in the pilot trial, participate in an early, individualized pelvic floor muscle training program\n\nThis study will provide important information about how the pelvic floor heals after childbirth, how structural changes are linked to symptoms, and whether early personalized training can help prevent long-term problems.",[152,26,153,154,155,156,157,158],"Urinary Incontinence","Bowel Symptoms","Postpartum","Physiotherapy and Rehabilitation","Pelvic Floor Muscle Training","Pelvic Floor","Recovery","2026-05-21",{"date":161,"type":40},"2026-05-27",{"date":163,"type":40},"2026-04-07",{"date":165,"type":20},"2029-12-31",{"name":167,"class":168},"Vastra Gotaland Region","OTHER_GOV",2,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":48},"100640259","development-and-validation-of-a-risk-prediction-model-for-de-novo-stress-urinary-incontinence-after-pelvic-floor-reconstruction-surgery-100640259","NCT07601282","Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction Surgery","Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction Surgery: A Case-Control Study","Inclusion Criteria:\n\n1. Patients with pelvic organ prolapse quantification (POP-Q) stage II or higher;\n2. Patients who require surgical treatment for pelvic organ prolapse;\n3. Patients with no evidence of urinary incontinence before surgery.\n\nExclusion Criteria:\n\n1. Patients confirmed to have urinary incontinence before surgery;\n2. Patients with urinary or reproductive system infections;\n3. Patients with a history of prior surgery for urinary incontinence;\n4. Patients who have undergone previous mesh repair surgery for pelvic organ prolapse;\n5. Patients with a history of psychiatric disorders, hearing impairment, or communication difficulties;\n6. Patients receiving hormone replacement therapy;\n7. Patients with neurodegenerative diseases such as stroke or multiple sclerosis, or neurological conditions such as spinal cord injury.","20 Years","90 Years",{"count":180,"type":20},382,"This observational study aims to develop a predictive model for the occurrence of new-onset stress urinary incontinence (SUI) after pelvic organ prolapse (POP) repair surgery in women. The primary questions it seeks to answer are:\n\nWhich risk factors and anatomical characteristics predispose women to new-onset stress urinary incontinence following pelvic organ prolapse repair surgery?\n\nFemale POP patients without any preoperative symptoms of urinary incontinence will receive telephone follow-ups at 3, 6, and 12 months after undergoing standard surgical treatment.",[26,116],[184],"Case-Control Study","2026-05-16",{"date":187,"type":40},"2026-05-22",{"date":189,"type":40},"2024-12-01",{"date":191,"type":20},"2026-12-31",{"name":193,"class":47},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100636535","the-finnish-uterine-prolapse-surgery-trial-the-fin-up-trial-100636535","NCT07566949","The Finnish Uterine Prolapse Surgery Trial (The Fin-UP Trial)","Manchester Procedure Versus Vaginal Hysterectomy for Women With Uterine Prolapse: A Multi-Center Randomized Controlled Study (The Fin-UP Trial)","Fin-UP","Inclusion Criteria:\n\n* Fit for elective vaginal surgery according to standard preoperative assessment\n* Women aged over 18 years\n* No previous POP surgery\n* Symptomatic POP stage 2 or higher, with uterine descent of at least stage 2 (POP-Q point C ≥ minus 1) and with POP-Q point D ≤ minus 1. Patients with concurrent anterior or posterior compartment defects will be included.\n\nExclusion Criteria:\n\n* Pregnancy or future plans of pregnancy\n* Active malignancy of any kind\n* Contraindications for uterine preservation, i.e. suspected cervical or uterine malignancy, abnormal cervical cytology, abnormal uterine bleeding, a history of endometrial hyperplasia with atypia, or a known hereditary cancer syndrome involving the uterus (e.g., Lynch syndrome). All patients will undergo a clinical examination and ultrasound assessment prior to recruitment. If clinically indicated, a Pap-smear and\u002For endometrial biopsy will be performed prior to inclusion.\n* Contraindication to vaginal hysterectomy (e.g. extensive intra-abdominal adhesions)\n* Patient's preference for uterine removal or preservation\n* Planned concomitant incontinence procedure\n* Inability to speak Finnish or Swedish, understand the purpose of the study, or commit to follow-up","100 Years",{"count":204,"type":20},426,[23],"The goal of this clinical trial is to compare the Manchester procedure and vaginal hysterectomy in treating patients with symptomatic uterine prolapse.\n\nThe main question it aims to answer is:\n\n• What is the difference in the success rates at the the two year follow-up\n\nParticipants will:\n\n* be randomized in either the Manchester procedure or vaginal hysterectomy group and operated as such\n* visit the clinic at 2 and 5 years after the operation\n* fill in questionnaires at 1, 2, 5 and 10 years after the operation",[208,87,26],"Uterine Prolapse",[210,90,211,212,91],"Uterine prolapse","Manchester procedure","Vaginal hysterectomy","2026-05-06",{"date":215,"type":40},"2026-05-11",{"date":217,"type":20},"2026-05",{"date":219,"type":20},"2041-12",{"name":221,"class":47},"Tampere University Hospital",6,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":80,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":250},"100609702","accelerometer-measured-early-recovery-after-prolapse-surgery-100609702","NCT07218016","Accelerometer Measured Early Recovery After Prolapse Surgery","AccelERate","Inclusion Criteria:\n\n* Subject has provided written informed consent\n* Ambulatory women undergoing laparoscopic, robotic, or vaginal reconstructive or obliterative surgery for apical prolapse\n* POP-Q \\>= Stage III\n* Willing to participate in a postoperative exercise regimen\n* Able to read and consent in English or Spanish\n* Willing and able to wear an accelerometer prior to and after surgery (including agreeing to the terms of service), use an electronic data capture software, and record daily events\n* Willing and able to install and use study-related smartphone app(s)\n* Anticipated hospital discharge \\\u003C= postoperative day 1\n\nExclusion Criteria:\n\n* Inability or unwillingness to adhere to the exercise intervention\n* Contraindication to medium-intensity exercise\n* Comorbidities preventing physical activity\n* Planned abdominal approach with laparotomy",{"count":231,"type":20},288,[23],"The AccelERate study will evaluate the physical recovery of patients who have undergone Pelvic Organ Prolapse (POP) surgery. This will be evaluated via a self-reported recovery questionnaire completed daily. Participants will wear an accelerometer device on their non-dominant wrist and be given either routine or exercise-focused postoperative instructions. The primary outcome will be a comparison of the number of days needed to reach self-reported \"mostly recovered\" status between randomly assigned instruction groups.",[64,26,87,235],"Pelvic Organ Prolapse, Patient Education",[237,26,238,239],"accelerometer","Post-operative Recovery","recovery activities","2026-04-24",{"date":242,"type":40},"2026-04-27",{"date":244,"type":40},"2025-10-02",{"date":246,"type":20},"2028-03-31",{"name":248,"class":249},"NICHD Pelvic Floor Disorders Network","NETWORK",7,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":270,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":286},"100631180","safety-and-performance-of-a-pelvic-floor-mesh-implant-for-laparoscopic-sacrocolpopexy-progynious-100631180","NCT07497321","Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)","ProGYNious","Inclusion Criteria:\n\n* Subject is a candidate for surgical repair of pelvic organ prolapse by ProGYNious implant according to the indication of the product under evaluation\n* Symptomatic pelvic organ prolapse with POP-Q \\>= 2\n* Age \\>18 years and ≤ 80years\n* Subject is willing and able to cooperate with follow-up examinations\n* Subject has been informed of the study procedures and the treatment and has signed an informed consent form\n\nExclusion Criteria:\n\n* previous or concurrent cancer which may affect the successful treament with laparoscopic mesh\n* known or suspected hypersensitivity to ProGYNious mesh or a component of ProGYNious mesh (Polypropylene)\n* known severe osteoporosis\n* pregnancy, suspected pregnancy and breastfeeding\n* bleeding of unknown cause in the genital area\n* previously irradiated patients in the pelvic area\n* drug or medication abuse, medical, psychological or social circumstances that could affect the patient's participation in the study or the evaluation of the study results\n* Any previous interventions with surgical mesh for pelvic organ prolapse and\u002For urinary incontinence\n* Unable to understand study requirements or is unable to comply with follow-up schedule\n* Contraindicated according to the instruction for use of the device\n* patients with an increased risk of infection or impaired wound healing (e.g. Diabetes mellitus with HbA1c \\>10, systemic autoimmune diseases, etc.)\n* concomitant Sling\u002FTVT procedure\n* life expectancy lower than follow-up period (e.g. ASA 4)\n* non-symptomatic pelvic organ prolapse\n* chronic pain syndrome\n* chronic respiratory disease (e.g. COPD, chronic cough)","80 Years",{"count":260,"type":20},100,[23],"The purpose of this clinical investigation is to collect clinical data about the ProGYNious Mesh based on a prospective clinical investigation. The primary objective is to verify the treatment outcome and success of the ProGYNious mesh implant in pelvic organ prolapse repair. The secondary objective is to confirm the safety, risks, complications and quality of life of ProGYNious as an implant for pelvic organ prolapse repair.",[26,264,265,266,267,268,157,269],"Synthetic Mesh","Laparoscopic Surgery","Gynecologic Laparoscopic Surgery","Sacrocolpopexy","Pelvic Floor Prolapse","Implant",[256,271,272,273,274,275],"A.M.I.","AMI","Agency for Medical Innovation","Y Mesh","Progyn","2026-03-24",{"date":278,"type":40},"2026-03-27",{"date":280,"type":20},"2026-04-15",{"date":282,"type":20},"2028-09-30",{"name":284,"class":285},"A.M.I. Agency for Medical Innovations GmbH","INDUSTRY",5,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":297,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":48},"100626818","effect-of-paracervical-block-on-postoperative-pain-after-vnotes-uterosacral-ligament-suspension-100626818","NCT07440576","Effect of Paracervical Block on Postoperative Pain After vNOTES Uterosacral Ligament Suspension","A Prospective Randomized Double-Blind Placebo-Controlled Trial Evaluating the Effect of Paracervical Block on Postoperative Pain After vNOTES Uterosacral Ligament Suspension","vNOTES-PB","Inclusion Criteria:\n\n* Female patients aged 18 years or older\n* Symptomatic pelvic organ prolapse requiring uterosacral ligament suspension (USLS)\n* Planned hysterectomy (vaginal hysterectomy or vNOTES hysterectomy) with concomitant BS or BSO, followed by vNOTES uterosacral ligament suspension\n* ASA physical status I-III\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to bupivacaine or local anesthetic agents\n* Chronic opioid use or chronic pain disorders\n* Previous pelvic radiation therapy\n* Severe hepatic or renal impairment\n* Coagulopathy or anticoagulant therapy contraindicating injection\n* Active pelvic infection\n* Pregnancy\n* Inability to understand the pain scoring system",{"count":296,"type":20},58,[23],"This study is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of paracervical block on early postoperative pain after vaginal natural orifice transluminal endoscopic surgery (vNOTES) uterosacral ligament suspension.\n\nEligible patients undergoing vNOTES uterosacral ligament suspension for benign gynecologic indications will be randomly assigned in a 1:1 ratio to receive either 10 mL of 0.5% bupivacaine or 10 mL of normal saline as a paracervical injection during surgery.\n\nThe primary outcome is postoperative pain assessed using the Visual Analog Scale (VAS) at 6 hours after surgery. Secondary outcomes include pain scores at multiple time points within 24 hours, total analgesic consumption, length of hospital stay, and patient satisfaction.\n\nThe study aims to determine whether paracervical block provides clinically meaningful pain reduction in the early postoperative period following vNOTES procedures.",[26,117],[301,302,303,304,305,306],"vnotes","uterosacral ligament suspension","paracervical block","bupivacaine","minimally invasive surgery","enhanced recovery","2026-03-09",{"date":309,"type":40},"2026-03-11",{"date":307,"type":40},{"date":312,"type":20},"2027-02",{"name":314,"class":168},"Erkan Gol",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":48},"100622114","are-there-benefits-of-using-energy-based-devices-for-opportunistic-salpingo-oophorectomy-during-vaginal-hysterectomy-compared-to-a-standard-cold-approach-100622114","NCT07379411","Are There Benefits of Using Energy-based Devices for Opportunistic Salpingo-oophorectomy During Vaginal Hysterectomy Compared to a Standard Cold Approach?","Energy-based Opportunistic Salpingo-oophorectomy During Vaginal Hysterectomy - is it Better Than Conventional \"Knot-and-cut\" Approach? A Randomized Controlled Study","Inclusion Criteria:\n\n* Women aged 18 years or older.\n* Scheduled to undergo vaginal hysterectomy for pelvic organ prolapse.\n* Recommended to undergo opportunistic salpingo-oophorectomy according to standard clinical indications.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Suspected or known pelvic malignancy.\n* Lack of informed consent.\n* Planned opportunistic salpingo-oophorectomy using a non-vaginal surgical approach.\n* Planned opportunistic salpingo-oophorectomy using a vNOTES (vaginal natural orifice transluminal endoscopic surgery) approach.\n* Intraoperative need to deviate from the assigned surgical technique due to anatomical or technical considerations.",{"count":323,"type":20},70,[23],"This study compares two methods for removing the fallopian tubes and ovaries during vaginal hysterectomy for pelvic organ prolapse.\n\nOne method uses an energy-based surgical device called LigaSure Maryland, which seals blood vessels using electrical energy. The other method is the standard surgical approach, which involves clamping, cutting, and suturing the tissue. The purpose of the study is to determine whether the use of the LigaSure device is as safe as, or more effective than, the standard technique, in terms of procedure duration, blood loss, postoperative pain, length of hospital stay, and complication rates.\n\nWomen who are scheduled to undergo vaginal hysterectomy for pelvic organ prolapse and for whom removal of the fallopian tubes and ovaries is recommended may participate in the study. Participants will be randomly assigned to one of two groups, receiving either the LigaSure technique or the standard surgical technique.\n\nThe decision to perform removal of the fallopian tubes and ovaries will be made before surgery based on standard medical indications. Participants will not be informed which surgical technique is used during their operation. Surgical outcomes between the two groups will be compared to evaluate safety and effectiveness.",[26],[34,328,329,330,331,332],"vaginal surgery","vaginal hysterectomy","salpingo-oophorectomy","prophylactic salpingo-oophorectomy","vaginal salpingo-oophorectomy","2026-01-26",{"date":335,"type":40},"2026-01-30",{"date":337,"type":40},"2025-10-16",{"date":339,"type":20},"2027-09",{"name":341,"class":168},"Wolfson Medical Center",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":351,"briefSummary":352,"conditions":353,"keywords":356,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":48},"100620602","vaginal-mesh-surgery-versus-robotic-assisted-abdominal-mesh-surgery-in-the-treatment-of-apical-prolapse---prospective-randomized-non-inferiority-study-100620602","NCT07359755","Vaginal Mesh Surgery Versus Robotic-assisted Abdominal Mesh Surgery in the Treatment of Apical Prolapse - Prospective Randomized Non-inferiority Study","A Comparative Analysis of Vaginal Mesh Surgery Versus Robotic-assisted Abdominal Mesh Surgery in the Treatment of Apical Genital Prolapse: a Prospective Randomized Non-inferiority Study.","Inclusion Criteria:\n\n* The study will include patients diagnosed with apical compartment genital prolapse of stage II or higher, who have an indication for surgical correction.\n\nExclusion Criteria:\n\n* The following exclusion criteria will apply: patients who are unable or unwilling to complete validated outcome assessment instruments; those requiring concomitant surgical procedures (e.g., hysterectomy or any other intervention that may alter pelvic floor anatomy);\n* individuals with a prior history of pelvic radiotherapy;\n* patients with congenital or acquired anomalies of the urogenital or gastrointestinal systems;\n* and those with medical conditions that constitute a contraindication to elective surgical intervention.",{"count":350,"type":20},86,[23],"The goal of this study is to compare vaginal mesh surgery with abdominal robotic-assisted mesh surgery for the treatment of genital prolapse in women. The main questions it seeks to answer are:\n\n* Is the objective cure rate for vaginal mesh surgery non-inferior to that of the abdominal approach?\n* Is the use of vaginal mesh as safe as abdominal mesh?",[26,87,354,355],"Mesh Reinforcement","Vaginal Apex\u002FUterine Prolapse",[90,357,358,359,267,210],"Vaginal prolapse","Vaginal mesh","Robotic-assisted sacrocolpopexy","2026-01-15",{"date":362,"type":40},"2026-01-22",{"date":364,"type":40},"2025-09-15",{"date":366,"type":20},"2030-06",{"name":368,"class":47},"University of Sao Paulo General Hospital",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":377,"enrollmentInfo":378,"targetDuration":380,"studyType":84,"phases":4,"briefSummary":381,"conditions":382,"keywords":386,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":103},"100603498","popq-associated-with-total-laparoscopic-hysterectomy-100603498","NCT07137299","POPQ Associated With Total Laparoscopic Hysterectomy","POPQ Associated With Total Laparoscopic Hysterectomy - Multicenter Prospective Observational Study - POP-LAP STUDY","POP-LAP","Inclusion Criteria:\n\n* persons who underwent total or subtotal hysterectomy for benign conditions regardless of the type of surgery\n* agree to participate and to follow-up\n\nExclusion Criteria:\n\n* having uterus\n* health state - ECOG \\>2\n* pelvic organ prolapse prior to the surgery\n* surgery due to malignant conditions (ovarian, cervical or endometrial cancer)","85 Years",{"count":379,"type":20},2000,"10 Years","The goal of this observational study is to evaluate the impact of different hysterectomy (removal of the uterus) techniques on the risk of pelvic organ prolapse (situation when one or more of your pelvic organs like your bladder, uterus, or rectum have dropped down or slipped out of their normal position, sometimes even bulging into the vagina) and urinary incontinence (leaking urine unexpectedly) in women aged 18-85 who underwent hysterectomy or supracervical hysterectomy (removing of the uterus without its cervix) for benign (not cancer) conditions.\n\nThe main question is: to check how different surgical technique (laparoscopic, with opening the abdomen, vaginal and robotic) increase the risk of pelvic organ prolapse or urinary incontinence There is no randomization or control group; comparisons will be made between surgery types based on clinical and questionnaire data.\n\nParticipants will:\n\n* Receive an invitation to participate if they underwent hysterectomy between 2021-2025.\n* Fill out validated quality of life questionnaires (P-QOL, POPDI-6, PFIQ-7) every two years.\n* Attend follow-up clinical pelvic exams every two years to assess vaginal cuff healing, pelvic organ prolapses (POP-Q system), and urinary symptoms.\n\nThis prospective, non-commercial, multicenter study plans to enroll 2,000 women and will run from July 1, 2025, to July 1, 2036",[383,384,385,26],"Uterine Fibroids (UF)","Abnormal Uterine Bleeding Unrelated to Menstrual Cycle","Endometrial Hyperplasia",[387,212,388,389,390,34],"Hysterectomy","Laparotomy","Laparoscopy","Robotic surgery","2025-08-15",{"date":393,"type":40},"2025-08-22",{"date":395,"type":20},"2025-10-01",{"date":397,"type":20},"2037-07-01",{"name":399,"class":47},"Medical University of Silesia",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":409,"briefSummary":410,"conditions":411,"keywords":414,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":286},"100598074","safety-and-performance-of-a-pelvic-floor-mesh-implant-latgynious-100598074","NCT07066761","Safety and Performance of a Pelvic Floor Mesh Implant (LatGYNious)","Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Lateral Suspension (LatGYNious)","Inclusion Criteria:\n\n* Symptomatic prolapse in one of the 3 compartments from grade 2 with or without uterus\n* Subject is candidate for a surgical treatment of pelvic organ prolapse\n* Subject is willing and able to cooperate with follow-up examinations\n* Subject has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes.\n\nExclusion Criteria:\n\n* Previous surgical treatment with a mesh implant for pelvic organ prolapse (mesh implant in anterior or posterior compartment)\n* Active immunotherapy which may negatively affect the treatment with a surgical mesh\n* Active cancer of the vagina \u002F cervix \u002F rectum\n* . known or suspected hypersensitivity to Polypropylene\n* Pregnancy\n* participation in another study at the same time\n* Unable to understand study requirements or is unable to comply with follow-up schedule\n* Contraindicated according to the instruction for use of the device",{"count":408,"type":20},85,[23],"The purpose of the clinical investigation is to verify that the investigational device (LatGYNious) is appropriate to significantly improve the pelvic organ prolapse in patients.",[26,412,413,265],"Genital Prolapse","Uterus Prolapse",[415],"Laparoscopic lateral suspension (LLS)","2025-07-15",{"date":418,"type":40},"2025-07-18",{"date":420,"type":40},"2025-07-01",{"date":422,"type":20},"2027-07",{"name":284,"class":285},{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":21,"phases":434,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":448,"locationsCount":169},"100595282","phase-3-vaginal-estrogen-for-improvement-of-outcomes-following-pelvic-organ-prolapse-surgery-100595282","NCT07030426","Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery","A Multi-center, Randomized, Open-label, Parallel-group, Feasibility-controlled Trial of Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery","VEPO","Inclusion Criteria\n\nParticipants must meet all the following inclusion criteria to be eligible for enrollment into the study:\n\n1. Participant who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n2. The participant has given written consent after the study has been explained according to local regulatory requirements and before any study specific procedures.\n3. Age ≥18 years at the time of consent.\n4. Undergoing an apical suspension (vaginal or abdominal, mesh or native tissue) for pelvic organ prolapse at one of the participating centers.\n5. Primary or recurrent prolapse surgery without a history of mesh surgery.\n6. Willing to complete surveys related to demographics, pelvic health and function, and sexual health and function.\n7. Plans to reside in the study area for at least 2 years after their surgery.\n\nExclusion Criteria\n\nAny individual meeting any of the following criteria is not eligible for participation in this study:\n\n1. Participant undergoing anterior and\u002For posterior repair only (no apical prolapse repair).\n2. Participant undergoing obliterative procedures.\n3. Participant with a history of mesh surgery for prolapse.\n4. Participant undergoing uterine sparing surgery.\n5. Participant with a contraindication to vaginal estrogen use, including but not limited to the following list, at the discretion of the study investigator:\n\n   * Patients who are hypersensitive to the drug or to any ingredient in the formulation or component of the container.\n   * Liver dysfunction or disease as long as liver function tests have failed to return to normal.\n   * Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer).\n   * Endometrial hyperplasia.\n   * Known, suspected, or past history of breast cancer.\n   * Undiagnosed abnormal genital bleeding.\n   * Known or suspected pregnancy\n   * Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial infarction, coronary heart disease).\n   * Partial or complete loss of vision due to ophthalmic vascular disease.\n   * Known thrombophilic disorders (e.g., protein C, protein S OR antithrombin deficiency); prothrombin mutation or anticardiolipin antibodies).\n6. Any conditions that, in the Investigator's judgement, may interfere with participant's ability to comply with study procedures or receipt of care, such as behavioral or cognitive impairment or neuropsychiatric illness.\n7. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine\u002Fproduct.",{"count":433,"type":20},180,[435],"PHASE3","This open-label randomized control trial will study the use of vaginal estrogen in the first six weeks after pelvic organ prolapse (POP) repair surgery. This is a pilot trial that will examine the feasibility of the study, focussing on recruitment rates. Participants will be randomized to one of three groups; (1) no vaginal estrogen for 6 weeks, (2) vaginal estrogen twice weekly for 6 weeks, or (3) vaginal estrogen daily for 6 weeks. Participants will be seen at 6 weeks post surgery, 6 months post surgery, 1 year and 2 years post surgery. Additional outcomes will include patient satisfaction, Genitourinary Syndrome of Menopause (GSM) symptoms, post-operative complications, adherence and safety.",[26],[34,439,440,441],"vaginal estrogen","pelvic organ prolapse surgery","pelvic organ prolapse repair","2025-06-20",{"date":444,"type":40},"2025-06-26",{"date":395,"type":20},{"date":447,"type":20},"2029-09-30",{"name":449,"class":47},"Queen's University",{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":146,"sex":458,"minAge":57,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":4},"100581309","impact-of-equestrian-sports-crossfit-and-gym-training-on-pelvic-floor-health-pelfisport--100581309","NCT06848634","Impact of Equestrian Sports, CrossFit, and Gym Training on Pelvic Floor Health (PELFISPORT )","Impact of Equestrian Sports, CrossFit, and Gym Training on Pelvic Floor Health in Athletes and Non-Athletes: A Cross-Sectional Study","PELFISPORT","Inclusion Criteria:\n\n* Adults 18 years or older.\n* Voluntary participation with signed informed consent.\n* Completion of the online survey.\n* For the sports groups (Equestrian, CrossFit, Gym, Other Sports):\n\n  * Minimum 2 years of experience in the sport.\n  * Minimum 2 training sessions per week.\n\nExclusion Criteria:\n\n* Individuals under 18 years old.\n* Participants who do not complete the survey.\n* Individuals with neurological conditions affecting mobility.\n* Individuals with mobility impairments unrelated to sports.\n* Sports participants with less than 2 years of experience or training less than twice per week.","ALL",{"count":460,"type":20},200,"This observational cross-sectional study investigates the impact of equestrian sports, CrossFit, and gym training on pelvic floor health in both athletes and non-athletes. The study aims to determine whether specific sports are associated with a higher risk of pelvic floor dysfunction, including urinary incontinence, pelvic organ prolapse, and chronic pelvic pain.\n\nParticipants will complete an online survey that collects demographic information, sports participation details, and pelvic floor health symptoms. The survey includes standardized questionnaires to assess pelvic floor function. Data will be analyzed to compare the prevalence of pelvic floor issues among different sports and between athletes and non-athletes.\n\nThe study seeks to provide insights into how sports participation influences pelvic health and to raise awareness of pelvic floor dysfunction in both male and female athletes.",[463,152,26,464],"Pelvic Floor Dysfunction","Chronic Pelvic Pain",[92,90,466,467,468,469,470,471],"Chronic pelvic pain","Equestrian sports","CrossFit","Gym training","Women's health","Physical activity","2025-02-26",{"date":474,"type":40},"2025-02-27",{"date":476,"type":20},"2025-02-28",{"date":478,"type":20},"2025-04-05",{"name":480,"class":47},"University of Oviedo"]